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Berberine is a natural compound extracted from Coptidis rhizoma, and accumulating proof has shown its
potent anti-tumor properties with diverse action on melanoma cells, including inhibiting cancer viability,
blocking cell cycle and migration. However, the mechanisms of berberine have not been fully clariﬁed. In
this study, we identiﬁed that berberine reduced the migration and invasion capacities of B16 cells, and
notably altered pluripotency of epithelial to mesenchymal transition associated factors. We found that
berberine also downregulation the expression level of p-PI3K, p-AKT and retinoic acid receptor a (RARa)
and upregulation the expression level of retinoic acid receptor b and g (RARb and RARg). These effects of
PI3 kinase inhibitor LY294002 treatment mimicked Berberine treatment except the expression level of
RARg. Moreover, Western blot analysis showed that the decreased PI3K and AKT phosphorylation,
increased the epithelial maker E-cadherin, and upregulation level of RARb while decreased the
mesenchymal markers N-cadherin and downregulation level of RARa by incubation with LY294002 in
mouse melanoma B16 cells. In conclusion, Our study reveal that berberine can reverse the epithelial to
mesenchymal transition of mouse melanoma B16 cells and may be a useful adjuvant therapeutic agent in
the treatment of melanoma through the PI3K/Akt pathway and inactivation PI3K/AKT could regulate
RARa/RARb expression.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over 90% of cancer-related deaths that can be contributed to the
metastasis [1]. Melanoma is the deadliest form of skin cancer
because of its tend to metastasize [2]. It is a relatively rare cancer in
China, but causes over 65% of skin cancer-related deaths [3]. Cancer
metastasis is a major cause for poor survival and prognosis of
melanoma patients. Therefore, decreasing the metastasis of mela-
noma is one of the important goal in medicine.
The Epithelial-to-mesenchymal transition (EMT) is a critical
mechanism in tumor cells metastasis [4]. During the process of
EMT, cancer cells gain mesenchymal characteristics and lose their
epithelial characteristics to become invasive [5]. Some studies
found that PI3K/Akt signaling pathway mediates the process of
EMT and has attracted wide attention as a novel target for the
prevention and treatment of metastatic tumors [6]. Activated PI3KSchool of Fundamental Med-
e, Guangzhou 510006, China.
Inc. This is an open access article uby tyrosine kinase leads to the oncogene AKT [7] and activated Akt
could phosphorylate a variety of substrates, thereby affecting kinds
of cellular processes, such as cell cycle, cellular growth, differenti-
ation, apoptosis, angiogenesis and migration [8]. In addition,
numbers of studies showed that PI3K/Akt pathway is associated
with other signaling pathways, including Ras, NF-кB, TGF-b, and
Wnt/b-catenin, to directly or indirectly induce the EMT [9].
Furthermore, previous study showed that All-trans retinoic acid
(ATRA) enhanced Akt activation regulation by RARa-Akt interaction
and the active form of Akt remarkably reduces expression levels of
the tumor suppressors RARb2 [10]. The PI3K/AKT pathway may be
also associated with Retinoid signaling pathway.
Berberine, an isoquinoline alkaloid, can be isolated from all
kinds of medicinal herbs including Coptis chinensis, Berberis vul-
garis, Berberis aristata, and Berberis aquifolium, many of which are
used in traditional medicines [11]. Berberine was conﬁrmed to
present comprehensive pharmacological actions, such as anti-
cancer, anti-inﬂammatory, and anti-microbial effects [12]. Recently,
berberine has been proved to possess anti-cancer activities. For
example, berberine was discovered to activate AMP-activatednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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migration and metastasis [13]. And berberine declined melanoma
cancer cell migration by decreasing the expressions of prosta-
glandin E2, prostaglandin E2 receptors and cyclooxygenase-2 [2].
Recently, some study showed that in Human Chondrosarcoma,
berberine induced G2/M arrest through activated PI3K/AKT cell line
[14]. Also, in neuroblastoma cells, berberine induced neuronal
differentiation via suppression of cancer stems cell and EMT [15].
However, the effects of berberine on melanoma metastasis and
the molecular mechanisms still remain unknown. Therefore, the
purpose of this study was to investigate the effect of berberine on
metastasis of mouse melanoma B16 cells and the underlying
mechanisms. These dates could provide a novel sight of the anti-
metastasis mechanisms of berberine.
2. Materials and methods
2.1. Cell lines and reagents
The murine melanoma B16 cells were cultured in RPMI 1640Fig. 1. (A) Cell viability analysis of B16 cells cultured in the presence of BBR for 24, 48 h or 72
48 h. The culture medium of the cells after treatment were detected the activity of MMPs us
treated with BBR (10 mM, 20 mM and 40 mM) and its control was measured by wound-healing
measured by transwell.medium supplemented with penicillin (100 U/ml), streptomycin
(100 mg/ml),10% fetal bovine serum (Hyclone) and incubated at
37 C with 5% CO2. Berberine were purchased from Chengdu
Mansite Pharmaceutical Co. Ltd. (Chengdu, China). MTT [3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide] was
from Sigma (St. Louis, MO, USA). LY294002 was purchased from
Calbiochem (San Diego, CA, USA).2.2. MTT assay
B16 cells were cultured in the 96-well plates for 24 h at a
seeding density of 6.0  103 cells before treated. After cells treat-
ment with berberine (5 mM, 10 mM, 20 mM, 40 mM, 80 mM, 160 mM)
for different times, the medium was removed and 100 ml of MTT
reagent (0.5 mg/ml) was added to each well for another 4 h of in-
cubation. At the end of the incubation time, the medium was
removed; intracellular formazanwas solubilized with 150 ml DMSO
and quantiﬁed spectrophotometrically (l ¼ 490 nm) with a
microplate reader Victor X3 (PerkinElmer, Waltham, MA, USA).h by MTT assay. (B) B16 cells were treated with berberine (10 mM, 20 mM and 40 mM) for
ing AmpliteTM Universal Fluorimetric MMP Activity Assay Kit.(C) Migration of B16 cells
.(D) Invasion of B16 cells treated with BBR(10 mM, 20 mM and 40 mM) and its control was
Fig. 2. (A) Expression of EMT markers E-cadherin, N-cadherin, Fibronectin, Vimentin, (B) and b-catenin, (C) and transcription factors Snail1, Slug, ZEB1 in B16 cells treated with
BBR(10 mM, 20 mM and 40 mM) and its control were analyzed by Western blotting. The bar graphs (mean ± SD) and representative images are shown. *p < 0.05, **p < 0.01,
***p < 0.001 compared with the B16 group.
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B16 cells (1.5  104 cells/well) were cultured in the upper
chamber with low-serum medium contained berberine, while
high-serum medium (15% FBS) was added to the lower chamber.
After 24 h of incubation at 37 C, cells were ﬁxed with 4% para-
formaldehyde, and stained with 0.1% crystal violet for 20 min. Then
dissolved the crystal violet in DMSO, and the OD value were
detected by Victor X3(PerkinElmer, Waltham, MA, USA) at 600 nm.
For wound healing assays, cells were seeded on six-well plates and
grown to conﬂuency. Then, the cells were gently scratchedwith tips
to create a mechanical wound and incubated in medium with 0.5%
FBS in the absence or presence of berberine for 24 h. Images were
taken at 0, 12 h and 24 h using a microscope (Leica, Jena, Germany).2.4. Western blot analysis
Cells were seeded in 6-well culture plates at a density of
3  105 cells/well and treated with berberine (10 mM, 20 mM and
40 mM) and LY294002 (20 mM) for 48 h. RIPA buffer mixed PMSF
(RIPA: PMSF ¼ 100:1) was used to harvest and lyse cells. The
samples were further incubated with the primary antibodies
against b-actin, E-cadherin, N-cadherin, vimentin, ﬁbronectin, b-
catenin, snail1, slug, ZEB1, RARa, RARb, RARg (Santa Cruz Biotech-
nology with 1:1000e1:2000 dilutions), PI3K, p-PI3K, AKT, p-AKT,
(CST Biotechnology with 1:1000e1:2000 dilutions) followed by
HRP (horseradish peroxidase)-labeled secondary. Goat anti-mouseIgG or anti-rabbit IgG (Santa Cruz Biotechnology) was used as the
secondary antibody. The hybridization signal was examined using
enhanced chemiluminescence (ECL). The relative intensities of the
blots were quantiﬁed by Quantity One (Bio-Rad, Hercules, CA, USA).
2.5. MMP activity assay
The activity of MMPs was detected with AmpliteTM Universal
Fluorimetric MMP Activity Assay Kit according to the standard
protocols. In brief, 3  105 cells were seeded onto 6-well plate and
treated with berberine (10 mM, 20 mM, 40 mM) and LY294002
(20 mM) for 48 h. Then 50 ml of supernatants from each well was
added to a 96 well plate for detection.
2.6. Statistical analysis
Data were statistical analyzed with SPSS 17.0. *p < 0.05,
**p < 0.01, ***p < 0.001 are determined as signiﬁcance. Value pre-
sented as the means ± standard deviation (SD) by GraphPad Prism
software (GraphPad Software, CA, USA).
3. Results
3.1. Berberine suppressed mouse melanoma B16 cells invasion and
migration in a dose-dependent manner
The cytotoxic effects of berberine on mouse melanoma B16 cells
Fig. 3. (A) Phosphorylation and expression of PI3K, phosphorylation and expression of AKT, (B) and the protein levels of RARa, RARb, and RARg in B16 cells treated with BBR(10 mM,
20 mM and 40 mM) and its control were analyzed byWestern blotting. The bar graphs (mean ± SD) and representative images are shown. *p < 0.05, **p < 0.01, ***p < 0.001 compared
with the B16 group.
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berberine signiﬁcantly inhibited cell proliferation of B16 cells in
both dose- and time-dependent manner. Meanwhile, the MMP
activities weremarkedly suppressed by berberinewith reduction in
a dose dependent manner (Fig. 1B, p < 0.001). Wound healing assay
was implemented to conﬁrm if berberine affects cell migration. The
result showed that 40 mM berberine suppressed B16 cell migration
by 50.5± 1.3% at 24 h (Fig. 1C). Berberine inhibited B16 invasion in a
dose-dependent manner, 40 mM of berberine inhibited the inva-
siveness of B16 cells by 67.53 ± 1.88% (Fig. 1D, P < 0.001).3.2. Berberine signiﬁcantly inhibited EMT of B16 melanoma cells
To determine whether berberine is associated with EMT, we
detected the expression of epithelial and mesenchymal phenotype
markers with western blotting. Berberine markedly upregulated
epithelial markers, such as E-cadherin. Berberine also signiﬁcantly
declined mesenchymal markers such as N-cadherin, and the
expression was downregulated by 95.26± 1.19% when B16 cells
were treated with 40 mM berberine (Fig. 2A, p < 0.01). Meanwhile,
berberine treatment inhibited ﬁbronectin and vimentin expres-
sions. Cadherin-bound b-catenin is needed for cell adhesion.
Western blot analysis showed that b-catenin protein levels were
decreased by berberine treatment (Fig. 2B). Furthermore, after
berberine treatments the expressions of the transcription factorssuch as Snail1, Slug and ZEB1 were signiﬁcantly decreased in a
dose-dependent manner (Fig. 2C).
3.3. Regulation of the mRNA and protein levels of PI3K/AKT and
RARs pathways by berberine
To investigate whether berberine inﬂuences PI3K/Akt signaling
in melanoma cells, we tested the protein levels of PI3K, its phos-
phorylation (p-PI3K), Akt and its phosphorylation (p-AKT) in
B16 cells in response to treatment with BBR(10 mM, 20 mM, and 40
mM). We found that berberine did not affect the protein levels of
total PI3K and AKT, but remarkably inhibited the phosphorylation
of the two kinases in a concentration-dependent manner. 40 mM
berberine signiﬁcantly decreased the protein of p-AKT with the
decline of 63.12 ± 1.3% (Fig. 3A). In addition, we examined the
expression of RARs with western blotting. The result showed that
compared to control group, berberine remarkably activated RAR
pathway in a dose-dependent manner through increasing the
protein expressions of RARb and RARg while decreasing that of
RARa (Fig. 3 B).
3.4. Berberine inhibited EMT via modulation of PI3K/AKT and RARa/
RARb pathways in B16 cells
To investigate the validity of our results, we detected whether
Fig. 4. (A) Migration and Invasion of B16 cells were treated with 20 mM LY294002 (LY, a PI3K inhibitor) alone or in combination with BBR (40 mM) for 24 h and its control was
measured by wound-healing and transwell. (B)B16 cells were treated with LY (20 mM) alone or in combination with BBR (40 mM) for 48 h. The culture medium of the cells after
treatment were detected the activity of MMPs using AmpliteTM Universal Fluorimetric MMP Activity Assay Kit. (C) B16 cells were treated with LY (20 mM) alone or in combination
with BBR (40 mM) for 48 h. Protein expression levels of E-cadherin, N-cadherin, p-PI3K, p-Akt, RARa, RARb, RARg were measured by Western blotting. The bar graphs (mean ± SD)
and representative images are shown. *p < 0.05, **p < 0.01, ***p < 0.001 compared with the B16 group.
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hibitor (LY294002) inhibited the EMT potential of B16 cells.
Compared to the control treatment, the migration and the invasion
ratio were signiﬁcantly decreased by LY294002 (20 mM). Account-
ing for a 50.8 ± 2.82% reduced in the migration and a 64.86 ± 2.71%
reduced in the invasion in B16 cells (Fig. 4A, p < 0.001). LY29002
treatment also resulted in a remarkable suppression effect on the
MMP activities on B16 cells (Fig. 4B). Furthermore, we examined
the effect of LY294002 on the levels of proteins including EMT
markers, PI3K/AKT and RARs pathway affect by Berberine, as
mentioned above. We found that LY294002 notably increased the
protein express of E-cadherin, while decreased that of N-cadherin,
p-PI3K, p-AKT. In addition, the protein level of RARa was reduced
but RARb was enhanced in cells exposed to LY294002. Then, the
RARg protein level was unchanged. (Fig. 4C). Therefore, LY294002
showed a down-regulation inﬂuence that was similar to that of
Berberine on B16 cells. These results suggested that berberine
suppressed the EMT of highly metastatic B16 melanoma cells via
the modulation of the PI3K/Akt and RARa/RARb (Fig. 4C).
4. Discussion
Cancer cell metastasis is a complex process including migration,invasion, adhesion, and proliferation [16]. Melanoma is the main
important cause of death in skin diseases and metastasis in early
stage, and metastasis is the primary reasons that cancer therapies
against melanoma fail. Therefore, novel metastasis-targeting anti-
tumor drugs are needed to be developed for themigratory potential
of melanoma cells. Berberine, as a pharmacological agent, treated a
kinds of human diseases has been documented in Asian countries
[12] and inhibited cancer metastasis [17]. Previous study found that
berberine could decrease the pulmonary metastasis in mice and
suppress invasion and migration ability of B16 F-10 melanoma cells
through inhibition of MMP [18]. Furthermore, berberine decreased
invasion and metastasis ability through COX-2/PGE2 mediated
JAK2/STAT3 pathway in colorectal cancer cells [19]. In the current
study, we found that berberine suppressed invasion and metastasis
of B16 cells and activated some signaling pathways.
Our study found that berberine inhibited cell viability, migration
and invasion of B16 cells (Fig. 1AeD). Previous study reported that
secreting extracellular proteases such as MMPs family are signiﬁ-
cant during cancer metastasis [20]. We found that berberine
signiﬁcantly decreased MMP activities (Fig. 1B). EMT, a biologic
process found in many types of epithelial cancers including mela-
noma, is able to increase cancer cells adhesion, invasion and
migration [21]. EMT process is initiated by transcription factors
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the promoter E-box, which suppressed E-cadherin transcription
leading to inhibit E-cadherin expression [22]. In addition, during
epithelialemesenchymal transition procession, cancer cells acquire
mesenchymal markers, including N-cadherin, vimentin, and
ﬁbronectin, followed by tumor metastasis, and proliferation at
distant sites [23]. Our data suggested that berberine altered
morphological characteristics of cells, which is similar to MET with
increased E-cadherin and decreased N-cadherin, vimentin, ﬁbro-
nectin and b-catenin (Fig. 2AeB). Then, berberine inhibited tran-
scriptional factor including snail1, slug, and ZEB1 (Fig. 2C). Our
results suggested that berberine reverses epithelial mesenchymal
transition and inhibits metastasis in mouse melanoma B16 cells.
The PI3K/AKT pathway is activated in a kinds of oncogenic
processes, including cell proliferation, apoptosis, and metastasis
[24]. It is well known that PI3K/AKT signaling pathway facilitates
EMT signal transition [25]. Moreover, the PI3K/PTEN signaling
pathway plays important roles in the cadherin switch by decreasing
E-cadherin expression and increasing N-cadherin expression in
melanoma cells [26]. In this study, we found that berberine
inhibited the protein levels of p-PI3K, and p-AKT when epithelial
mesenchymal transition was reversed in mouse melanoma
B16 cells. Furthermore, some study showed that over-expression of
RARa enhanced Akt phosphorylation in COS-7 cells and interacted
with PI3k at the plasma membrane [27]. However, inducing the
PI3k/Akt signaling pathway resulted in down-regulation the mRNA
and protein levels of RARb2 [28]. In addition, RARgacts as a tumor
suppressor or oncogene in different cancers, depending on the cell-
speciﬁc context [29]. For example, Gui-Li Huang et al. suggested
that RARg knockdown decreased metastatic abilities in CCA cells
[30]. Our study showed that berberine reduced the protein levels of
RARawhile enhanced the protein levels of RARb and RARg (Fig. 3B).
PI3K/AKT signaling pathway was closely associated with RARs.
Moreover, LY294002, a PI3K/Akt pathway inhibitor, is used to
conﬁrm that the suppressive effect of berberine on the EMT process
in melanoma B16 cells involves the regulation of the PI3K/Akt
pathway and RARa/RARb proteins (Fig. 4AeC). Therefore we sug-
gested that berberine inactivated PI3K/AKT signaling pathway
leading to down-regulation RARa and up-regulation RARb.
In conclusion, this study suggested that berberine could inhibit
cells invasion and migration of mouse melanoma through inhibit-
ing EMT-related protein. The mechanism of the reducing EMT by
berberine might be regulation via cross-talk between PI3K/AKT and
RARa/RARb. Furthermore, our study suggests that berberine should
be developed as a natural compounds with low-toxicity and low-
lost for clinical cancer treatment.Conﬂict of interest
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